Margarida Maia, PhD, science writer —

Almost two-thirds of a group of 108 secondary progressive multiple sclerosis (SPMS) patients being treated with Mayzent (siponimod) remained stable for at least one year, and about 1 in 5 of them showed improvements, a real-world study from Germany found. Nearly one-third of the total 227 SPMS patients evaluated…

Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences that’s being tested for multiple sclerosis and other autoimmune and nervous system diseases, was found to be safe and able to modulate the immune system in healthy volunteers, a study has found. Researchers failed to detect antibodies…

An upcoming observational clinical trial will assess how adherence to treatment with the portable neuromodulation stimulator (PoNS) device, used in the clinic and later at home, improves gait in people with multiple sclerosis (MS). Sponsored by Helius Medical Technologies, the device’s developer, the open-label Therapeutic…

A group of four patients have entered a special program where they’ll gain access to foralumab nasal spray, an experimental therapy that’s being tested for non-active secondary progressive multiple sclerosis (SPMS). This is the first group of four who entered Tiziana Life Sciences’ intermediate-size expanded access program.

A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…

Four weeks of treatment with nabiximols — an oral spray containing compounds found in the cannabis plant — significantly reduced spasticity and generally improved arm and hand function in multiple sclerosis (MS) patients with moderate-to-severe spasticity, according to a small pilot study in Italy. Notably, after nabiximols, patients showed…

A research team at Marquette University has received a $3.34 million grant from the National Institutes of Health (NIH) to test whether high-intensity exercise on a “shaky” treadmill — one that moves unexpectedly — can help people with multiple sclerosis (MS) retain a sense of balance and walk faster. The…

The presence of iron rim lesions, which are regions of chronic inflammation seen on MRI scans, may be linked to a more severe disease course in people with multiple sclerosis (MS), according to a recent study. The findings suggest the presence and number of iron rim lesions could serve…

Three months of once-weekly sessions of high-intensity resistance training — consisting of strength exercises followed by a short recovery between sets — effectively eased fatigue in multiple sclerosis (MS) patients experiencing low energy and tiredness, a trial in Sweden shows. This intervention also lessened feelings of depression and anxiety,…

The Accelerated Cure Project (ACP) for multiple sclerosis (MS) is teaming up with Quest Diagnostics to study how MS patients respond to COVID-19 vaccines. “Understanding the immune response to the COVID-19 vaccine doses in a longer-term study in people with MS will provide tremendous insights into not…

A machine learning approach based on eye scans was employed by researchers to diagnose multiple sclerosis (MS) in children with up to 80% accuracy. Optical coherence tomography (OCT) scans also provided enough data to diagnose other demyelinating diseases with 75% accuracy. OCT is an imaging tool that uses…

The first symptoms of relapsing-remitting multiple sclerosis (RRMS) have been appearing increasingly later in life, according to a Spanish study covering nearly five decades. From the 1970s through the 2010s, the average age at disease onset rose by more than 10 years in both men and women, its researchers…

The U.S. Food and Drug Administration (FDA) has agreed to review an application requesting that Polpharma Biologics‘ natalizumab, a biosimilar of Tysabri, be approved to treat relapsing forms of multiple sclerosis (MS). Its intended U.S. use is for the same indications as the approved name-brand medicine, covering clinically isolated…

Note: This story was updated July 20, 2022, to correct the headline to reflect that Soliris might be a potential treatment for progressive MS based on data from a single case report. A female patient with undiagnosed secondary progressive multiple sclerosis (SPMS) was placed on Soliris (eculizumab)…

Black Americans with multiple sclerosis (MS) have a higher chance of having uncontrolled high blood pressure (hypertension), despite being more likely to receive anti-hypertensive medication than white patients, a large study found. Further studies are needed to confirm these findings and…

Higher numbers of immune cells circulating in the bloodstream may mean a greater likelihood of developing multiple sclerosis (MS), according to a study based on a large pool of genetic data in people of European ancestry. One particular type of immune cell, called natural killer (NK) cells, was linked…

Dysport (abobotulinumtoxinA), a form of purified botulinum toxin, has received a positive opinion in Europe for managing urinary incontinence in adults with neurogenic detrusor overactivity (NDO), or overactive bladder. The opinion is specifically for those who experience bladder issues due to multiple sclerosis (MS) or spinal cord…

Women who were exposed to sexual or emotional abuse as children may be at an increased risk of developing multiple sclerosis (MS) later in life, according to a large study in Norway. The risk was even higher among patients who experienced a combination of two or more types of abuse in…

This year’s Scientific Breakthrough Award, funded by the American Brain Foundation, has been awarded to Stephen Hauser, MD, for helping to understand the genetic basis, immune processes, and treatment of multiple sclerosis (MS). The award recognizes the work of an individual or a team whose research has contributed…

COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people with relapsing-remitting multiple sclerosis (RRMS), an Iranian study suggests. The study was relatively small, the researchers noted, indicating that more research is needed in the future to determine the…

A researcher in Barcelona, Spain, has been chosen to receive the 2022 John Dystel Prize for his work advancing the understanding, diagnosis, and treatment of multiple sclerosis (MS). The $40,000 prize, given jointly by the National MS Society and the American Academy of Neurology (AAN), will be…

PIPE-307, an investigational myelin-restoring medication being developed by Pipeline Therapeutics for the treatment of multiple sclerosis (MS), appears to be safe and well tolerated in healthy adults. The results are from a Phase 1 clinical trial (NCT04725175) that evaluated the safety and tolerability of PIPE-307 in 70…

Treatment with an autologous hematopoietic stem cell transplant (aHSCT) seems to reboot the immune system in multiple sclerosis (MS) patients for at least three years, a small study found. The study, “Sustained immunotolerance in multiple sclerosis after stem cell transplant,” was published in Annals of Clinical and…

This year’s Harry Weaver Neuroscience Scholar Award, funded by the National Multiple Sclerosis (MS) Society, has gone to a Yale University researcher who is searching for biomarkers of radiologically isolated syndrome (RIS) in children. RIS occurs when imaging findings on MRI scans are similar to those seen in people…

Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus (EBV), a common virus thought to greatly increase the risk of multiple sclerosis (MS). The technology employs off-the-shelf cytotoxic T-cells — a type of white blood cell that can…

Tecfidera (dimethyl fumarate) appears to have similar benefits to Gilenya (fingolimod) in preventing relapses and the loss of motor function and cognition in people with multiple sclerosis (MS), a study with real-world data found. The two medications also led to similar findings on MRI scans, including in…

Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…

Cognition-targeting exercise, when combined with cognitive behavioral therapy (CBT) — a type of talk therapy — may further ease fatigue and other symptoms in people with multiple sclerosis (MS), a study found. The study, “The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized…

Donations to the Multiple Sclerosis Society of Canada through the end of this year will be double matched, meaning each donation will go three times as far in supporting Canadians with multiple sclerosis (MS) and in advancing research into the disease. All donations received until midnight on Dec.

People with a higher genetic risk for multiple sclerosis (MS) are significantly more likely to develop the disease at an earlier age, a large study found. Specifically, those with the highest genetic risk were on average five years younger at the time their symptoms started than those with the…